Protagonist Therapeutics, Inc. PTGX 深 沪
已收盘 08-21 16:00:00 美东时间
154.32
+3.630
+2.41%
华盛通- 最 高154.95
- 今 开152.10
- 成交量 40.25万股
- 最 低 150.82
- 昨 收 150.69
- 总市值 99.86亿
- 52周最高 160.81
- 市盈率 静 --
- 换手率 0.62%
- 52周最低 54.50
- 委 比 92.27%
- 总股本 6470.83万
- 历史最高 160.81
- 量 比 0.74
- 振 幅 2.74%
- 历史最低 4.47
- 每 手 1
- 风险率 23.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $112 to $178.
08-17 20:49
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma plc (NASDAQ:RPRX) on Wednesday entered into a $100 million funding agreement with Zealand Pharma in exchange for economic rights related to Zealand’s product, Rusfertide (PTG-300). This strategic move is expected to bolster Royalty Pharma’s portfolio and enhance its revenue streams. T...
08-14 01:07
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Goldman Sachs analyst Richard Law upgraded Protagonist Therapeutics Inc (NASDAQ:PTGX) from Neutra...
08-10 20:07
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight and raises the price target from $151 to $153.
08-06 22:48
财报速睇 | Protagonist Therapeutics, Inc. 2026财年Q2营收2.13亿美元，同比增长3749.2%；归母净利润1.63亿美元，扭亏为盈
华盛资讯8月6日讯，Protagonist Therapeutics, Inc.公布2026财年Q2业绩，公司Q2营收2.13亿美元，同比增长3749.2%，归母净利润1.63亿美元，扭亏为盈。
08-06 08:47
Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the analyst consensus estimate of $1.66 by 37.95 percent. This is a 516.36 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $213.4...
08-06 06:07
财报速睇 | Protagonist Therapeutics, Inc. 2026财年Q2营收2.13亿美元，同比增长3749.2%；归母净利润1.63亿美元，扭亏为盈
华盛资讯8月6日讯，Protagonist Therapeutics, Inc.公布2026财年Q2业绩，公司Q2营收2.13亿美元，同比增长3749.2%，归母净利润1.63亿美元，扭亏为盈。
08-06 04:48
美股大行评级 | 美银上调AMD目标价从550美元升至620美元；IBM暴跌25%！大摩上调目标价升至293美元，汇丰下调评级至"卖出"目标价降至191美元
今日重点评级关注：Keybanc：维持迈威尔科技"超配"评级，目标价从385美元升至400美元；丰业银行：维持科尔黛伦矿业"跑赢大市"评级，目标价从27.5美元升至28.5美元
07-15 10:22
